Estimating outcomes and cost effectiveness using a single-arm clinical trial: ofatumumab for double-refractory chronic lymphocytic leukemia

Hatswell, AJ; Thompson, GJ; Maroudas, PA; Sofrygin, O; Delea, TE

Hatswell, AJ (reprint author), BresMed, 84 Queen St, Sheffield S1 2DW, S Yorkshire, England.

COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2017; 15 ( ):

Abstract

Background: Ofatumumab (Arzerra (R), Novartis) is a treatment for chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab [double refra......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索